BENFO-biomo 300 mg benfotiamine, vitamin b1 deficiency

biomo pharma GmbH

Sale price £39.99 Regular price £50.00

Tax included. Shipping calculated at checkout.

BENFO-biomo 300 mg benfotiamine film-coated tablets, vitamin b1 deficiency

active substance benfotiamine

For medicines: Read the leaflet on the risks and side effects and ask your doctor or pharmacist.

application areas

The drug is given primarily in the case of proven deficiency states, when the vitamin B1 deficiency cannot be remedied through nutrition.
- Treatment of vitamin B1 deficiency

Application BENFO-biomo 300 mg benfotiamine, vitamin b1 deficiency Notes

The total dose should not be exceeded without consulting a doctor or pharmacist.

Type of application?
Take the medicine with liquid (e.g. 1 glass of water).

Duration of use?
The duration of use depends on the type of symptoms and/or the course of the disease and the success of the treatment. It should therefore be determined in consultation with your doctor.
To treat nerve diseases caused by a lack of vitamin B1, the drug should be used for at least 4 weeks at the beginning. Further treatment depends on the success of the treatment.

So far no overdose symptoms are known. If in doubt, consult your doctor.

In general, pay attention to a conscientious dosage, especially for infants, small children and the elderly. If in doubt, ask your doctor or pharmacist about any effects or precautions.

A dosage prescribed by the doctor may deviate from the information on the package leaflet. Therefore, since the doctor adjusts them individually, you should use the medicine according to his instructions.
General dosage BENFO-biomo 300 mg benfotiamine, vitamin b1 deficiency recommendation:
Adult 1/2-1 tablet 1 time per day regardless of the meal


How does the ingredient of the medicine work?

The active ingredient benfotiamine is a fat-soluble precursor (prodrug) of thiamine (vitamin B1) and is very well absorbed in the body and quickly converted into its effective form. Like thiamine (vitamin B1), the active ingredient is essential for the functioning of the nervous system and plays an important role in carbohydrate metabolism.

BENFO-biomo 300 mg benfotiamine, vitamin b1 deficiency composition

based on 1 tablet
300 mg benfotiamine
+ Cellulose, microcrystalline
+ Povidone K30
+ Croscarmellose sodium
+ talc
+ Silica, colloidal
+ Glycerol dibehenate
+ Opadry II white
+ poly(vinyl alcohol)
+ titanium dioxide
+ Macrogol 3350
+ talc


What speaks against an application?

- Hypersensitivity to the ingredients

Which age group should be considered?
- Children and adolescents under the age of 18: The medicine should not normally be used in this age group.

BENFO-biomo 300 mg benfotiamine, vitamin b1 deficiency Hints

What should you consider?
- Be careful if you are allergic to binding agents (e.g. carboxymethyl cellulose with the E number E 466)!
- There may be medicines with which interactions occur. You should therefore generally tell your doctor or pharmacist about any other medicine you are already using before starting treatment with a new medicine. This also applies to medicines that you buy yourself, use only occasionally or have been using for some time.

What about pregnancy and lactation?
- Pregnancy: consult your doctor. Various considerations play a role in whether and how the drug can be used during pregnancy.
- Breast-feeding: consult your doctor or pharmacist. He will examine your particular starting position and advise you accordingly as to whether and how you can continue breastfeeding.

If you have been prescribed the drug despite a contraindication, talk to your doctor or pharmacist. The therapeutic benefit can be higher than the risk that the use entails in the event of a contraindication.

side effects

What adverse effects may occur?

- Hypersensitivity
- Hives (urticaria)
- Skin rash
- Gastrointestinal tract disease
- Nausea
- Gastrointestinal complaints

If you notice any discomfort or changes during treatment, contact your doctor or pharmacist.

For the information at this point, side effects are primarily taken into account that occur in at least one in 1,000 patients treated.